Introduction – Core User Needs & Industry Context

Veterinary emergency clinics, specialty hospitals, and biomedical research laboratories require blood products from companion animals (dogs, cats) for transfusions, diagnostics, and research. Unlike human blood banking, veterinary blood products face unique challenges: limited donor availability, lack of standardized blood typing, and shorter shelf life. Pet blood products — materials extracted, separated, or processed from companion animal blood — solve these challenges. These products are used for direct transfusions, veterinary medicine, biomedical research, and even pet food and nutrition. Collection, processing, and preservation must adhere to strict veterinary protocols to ensure safety and efficacy. According to the latest industry analysis, the global market for Pet Blood Products was estimated at US$ 472 million in 2025 and is projected to reach US$ 640 million by 2032, growing at a CAGR of 4.5% from 2026 to 2032.

Global Leading Market Research Publisher QYResearch announces the release of its latest report "Pet Blood Products - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Pet Blood Products market, including market size, share, demand, industry development status, and forecasts for the next few years.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096611/pet-blood-products

1. Core Keyword Integration & Product Classification

Three key concepts define the pet blood products market: Veterinary Transfusion Medicine, Companion Animal Blood Banking, and Canine/Feline Diagnostic Reagents. Based on product type, pet blood products are classified into five categories:

Whole Blood: Collected with or without anticoagulant. Used for emergency transfusions (trauma, hemorrhage). ~30% market share.

Blood Cells: Packed red blood cells (pRBCs). Used for anemia treatment. ~25% share.

Serum: Clotted blood, cell-free. Used for diagnostic assays (ELISA, immunology). ~20% share.

Plasma: Fresh frozen plasma (FFP). Used for clotting factor deficiencies. ~15% share.

Others (platelets, cryoprecipitate): Specialty applications. ~10% share.

2. Industry Layering: Veterinary Medicine vs. Biomedical Research – Divergent Requirements

Aspect Veterinary Medicine Biomedical Research
Primary application Emergency transfusions, surgery support Drug development, disease models
Key requirement Cross-matching, pathogen screening Defined antigen profiles, traceability
Preferred product Whole blood, pRBCs, plasma Serum, plasma, RBCs
Blood typing requirement Essential (DEA 1.1 for dogs, A/B for cats) Variable
Market share (2025) ~70% ~20%
Exclusive observation: The veterinary medicine segment dominates (70% share), driven by emergency and specialty veterinary care expansion. The biomedical research segment is fastest-growing (CAGR 5.5%), fueled by animal model studies.

3. Canine vs. Feline Blood Products – Key Differences

Feature Canine (Dog) Feline (Cat)
Major blood types DEA 1.1 (positive/negative) Type A (99% domestic), Type B (rare), AB
Universal donor DEA 1.1 negative Type B (rare), AB
Transfusion reaction risk Moderate (sensitization) High (Type A to Type B)
Cross-matching Recommended Required (before first transfusion)
Blood volume (donor) 450 mL (standard unit) 50-60 mL (small unit)
Common veterinary transfusion indications:

Indication Preferred Product Canine Feline
Acute hemorrhage (trauma) Whole blood ✓ ✓
Chronic anemia Packed RBCs ✓ ✓
Coagulopathy Fresh frozen plasma ✓ ✓
Thrombocytopenia Platelets ✓ (less common)
Hypoproteinemia Plasma ✓ ✓
4. Recent Data & Technical Developments (Last 6 Months)

Between Q4 2025 and Q1 2026, several advancements have reshaped the pet blood products market:

Canine universal donor programs: DEA 1.1 negative donor dog registries expanded, increasing availability of universal donor blood for emergency transfusions. This segment grew 20% in 2025.

Feline blood typing kits: Point-of-care blood typing (card agglutination) reduces transfusion reaction risk. Adoption grew 25% in 2025.

Pathogen reduction technology: Ultraviolet + riboflavin treatment for canine plasma reduces transfusion-transmitted disease risk. First commercial products launched Q4 2025.

Policy driver – Veterinary blood banking standards (2025 update) : American College of Veterinary Internal Medicine (ACVIM) guidelines for donor screening and product storage, driving quality improvements.

User case – Veterinary emergency hospital (US) : A 24-hour emergency hospital implemented a DEA 1.1 negative canine donor program. Results: universal donor blood available for 80% of emergencies, transfusion reaction rate reduced from 5% to <1%, and cross-matching eliminated for DEA 1.1 negative recipients.

Technical challenge – Short shelf life of whole blood: Canine whole blood shelf life (21-35 days) limits availability. Solutions include:

Packed RBCs with additive solutions (extend to 42 days)

Frozen blood products (glycerolized RBCs, 1 year)

Donor recruitment programs (sustained supply)

5. Competitive Landscape & Regional Dynamics

Company Headquarters Key Strength
Lampire Biological USA Canine/feline blood products
Plasvacc USA USA Veterinary plasma products
ABRI (Animal Blood Resources) USA National blood bank network
IndyVet Blood Bank USA Regional blood banking
APC (Agricultural Protein) USA Animal-derived products
Regional dynamics:

North America largest (55% market share), led by US (advanced veterinary care, specialty hospitals)

Europe second (25%), with UK and Germany

Asia-Pacific fastest-growing (CAGR 6%), led by China (pet ownership growth, veterinary expansion), Japan, Australia

Rest of World (5%), emerging

6. Segment Analysis by Product and Application

Segment Characteristics 2024 Share CAGR (2026-2032)
By Product
Whole Blood Emergency transfusions ~30% 4%
Blood Cells (pRBCs) Anemia treatment ~25% 5%
Serum Diagnostic assays ~20% 4.5%
Plasma Coagulopathy ~15% 5%
Others Specialty ~10% 4.5%
By Application
Veterinary Medicine Clinical transfusions ~70% 4.5%
Biomedical Research Animal models ~20% 5.5%
Others (nutrition, diagnostics) Niche ~10% 4%
The packed RBCs segment is fastest-growing among products (CAGR 5%). The biomedical research application leads growth (CAGR 5.5%).

7. Exclusive Industry Observation & Future Outlook

Why pet blood products are essential:

Clinical Scenario Blood Product Lifesaving Role
Hit-by-car trauma Whole blood, pRBCs Restores oxygen-carrying capacity
Immune-mediated hemolytic anemia (IMHA) pRBCs (cross-matched) Supports through hemolytic crisis
Rat poison ingestion (anticoagulant) Fresh frozen plasma Replaces clotting factors
Surgical hemorrhage Whole blood, pRBCs Maintains perfusion
Blood typing in veterinary medicine:

Species Major Blood Types Universal Donor Prevalence
Canine DEA 1.1 (positive/negative) DEA 1.1 negative 40-60% negative
Feline Type A, Type B, Type AB Type B (rare) A: 90-99%, B: 1-10%
Equine A, C, Q A negative (varies) Variable
Pet ownership growth impact:

US pet ownership: 70% of households (2025), up from 67% (2020)

Veterinary spending: US$ 40+ billion annually

Emergency/specialty referral hospitals: 15% annual growth

Cost structure:

Product Cost per Unit (US$) Notes
Canine whole blood 150-300 Donor screening, processing
Canine pRBCs 200-400 Additive solution, extended shelf life
Feline blood (Type A) 100-200 Smaller volume (50-60 mL)
Feline blood (Type B) 300-500+ Rare donor, limited availability
Fresh frozen plasma 100-250 Canine, feline
Donor recruitment challenges:

Weight requirement: Dogs >25 kg, cats >4.5 kg

Health screening: Infectious disease testing (vector-borne, viral)

Owner compliance: Regular donation schedules

By 2032, the pet blood products market is expected to exceed US$ 640 million at 4.5% CAGR.

Regional outlook:

North America largest (55%), with advanced veterinary care

Asia-Pacific fastest-growing (CAGR 6%) — China pet ownership growth

Europe second (25%)

Rest of World (5%), emerging

Key barriers:

Limited donor availability (weight, health requirements)

Short shelf life (21-35 days for whole blood)

Blood typing complexity (feline alloantibodies cause severe reactions)

Regulatory variability (no universal veterinary blood banking standards)

Cost of pathogen screening (increases product price)

Market nuance: The pet blood products market is mature but growing steadily (4.5% CAGR). Veterinary medicine dominates (70% share). North America leads (55%) with advanced specialty veterinary care. Asia-Pacific fastest-growing (6% CAGR) with pet ownership expansion. Packed RBCs (anemia treatment) is fastest-growing product segment (5% CAGR). Key trends: (1) universal donor programs, (2) point-of-care blood typing, (3) pathogen reduction technology, (4) veterinary blood banking standards.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp